Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Infectious Diseases

• Publication date

  1997-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/514055PMID 9237703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention of hepatitis A.

  1998cited by this paper
• Probability of heterosexual transmission of HIV.

  1997cited by this paper
• Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

  1996cited by this paper
• Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

  1996cited by this paper
• Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV.

  1996cited by this paper
• A Resting Cell Assay for Improved Detection of Antibody-Mediated Neutralization of HIV Type 1 Primary Isolates

  1995cited by this paper
• Safety and Immunogenicity of a Recombinant HIV Type 1 Glycoprotein 160 Boosted by a V3 Synthetic Peptide in HIV-Negative Volunteers

  1995cited by this paper
• Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

  1995cited by this paper
• Neutralization of primary HIV‐1 isolates by anti‐envelope monoclonal antibodies

  1995cited by this paper
• Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV‐1SF2

  1995cited by this paper
• HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

  1994cited by this paper
• The prevention of hepatitis.

  1994cited by this paper
• In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

  1994cited by this paper
• Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains

  1994cited by this paper
• Comparison of the immune response to recombinant gp120 in humans and chimpanzees

  1994cited by this paper
• Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

  1993cited by this paper
• Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection

  1993cited by this paper
• Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1

  1993cited by this paper
• Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.

  1993cited by this paper
• Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

  1993cited by this paper
• Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.

  1993cited by this paper
• Diversification of HIV-1 Strains after Infection from a Unique Source

  1993cited by this paper
• Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains

  1993cited by this paper
• Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120

  1993cited by this paper
• Monoclonal Antibodies to the Extracellular Domain of HIV-1IIIB gp160 that Neutralize Infectivity, Block Binding to CD4, and React with Diverse Isolates

  1992cited by this paper
• Monoclonal Antibodies to the C4 Region of Human Immunodeficiency Virus Type 1 gp120: Use in Topological Analysis of a CD4 Binding Site

  1992cited by this paper
• HIV-1 genomic RNA diversification following sexual and parenteral virus transmission.

  1992cited by this paper
• Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

  1992cited by this paper
• Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule

  1992cited by this paper
• Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

  1992cited by this paper
• Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene

  1991cited by this paper
• HIV epidemiology: past, present, and future

  1991cited by this paper
• Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

  1991cited by this paper
• Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

  1991cited by this paper
• Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees

  1990cited by this paper
• Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

  1990cited by this paper
• Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

  1990cited by this paper
• HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain

  1990cited by this paper
• Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

  1990cited by this paper
• Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.

  1989cited by this paper
• An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.

  1989cited by this paper
• Single amino-acid changes in HIV envelope affect viral tropism and receptor binding

  1989cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity.

  1988cited by this paper
• Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex

  1988cited by this paper
• Envelope sequences of two new United States HIV-1 isolates.

  1988cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

  1986cited by this paper
• Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.

  1985cited by this paper
• Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

  1984cited by this paper
• The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.

  1982cited by this paper

• Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design

  2021cites this paper
• Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens

  2019cites this paper
• Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins.

  2019cites this paper
• Lessons from HIV-1 vaccine efficacy trials

  2016cites this paper
• Mutational Immune Escape in HIV-1 Infection

  2015cites this paper
• Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.

  2015cites this paper
• HIV-1 Mutational Escape from Host Immunity

  2014cites this paper
• HIV-1 Envelope Proteins and V1/V2 Domain Scaffolds with Mannose-5 to Improve the Magnitude and Quality of Protective Antibody Responses to HIV-1*

  2014cites this paper
• Sieve analysis in HIV-1 vaccine efficacy trials.

  2013cites this paper
• Sendai Virus Vector

  2013cites this paper
• Development of Vaccines Using SeV Vectors Against AIDS and Other Infectious Diseases

  2013cites this paper
• Who Subsequently Acquire HIV-1 Infection Responses in HIV Vaccine Trial Participants Virus Type 1 (HIV-1)-Specific T-Cell Induction of Human Immunodeficiency

  2012cites this paper
• Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding

  2012cites this paper
• Antibody epitope exposure and neutralization of HIV-1.

  2010cites this paper
• Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

  2010cites this paper
• Biometrika Trust Maximum Likelihood Estimation in Semiparametric Selection Bias Models with Application to AIDS Vaccine

  2010cites this paper
• HIV-1 vaccine design: Harnessing diverse lymphocytes to conquer a diverse pathogen

  2009cites this paper
• Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies

  2009cites this paper
• Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine

  2009cites this paper
• SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

  2009cites this paper
• HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

  2008cites this paper
• Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

  2007cites this paper
• A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

  2007cites this paper
• A Multi-Vector, Multi-Envelope HIV-1 Vaccine

  2007cites this paper
• Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses in HIV Vaccine Trial Participants Who Subsequently Acquire HIV-1 Infection

  2006cites this paper
• HIV vaccines: brief review and discussion of future directions

  2005cites this paper
• A modified false discovery rate multiple‐comparisons procedure for discrete data, applied to human immunodeficiency virus genetics

  2005cites this paper
• Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

  2005cites this paper
• HIV vaccine rationale, design and testing.

  2005cites this paper
• Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells.

  2004cites this paper
• The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection

  2004cites this paper
• Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

  2004cites this paper
• SAFETY AND ETHICAL CONSIDERATION OF AIDS VACCINE

  2004cites this paper
• DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade

  2004cites this paper
• Commonly Induced upon Infection Isolates to Neutralization by Antibodies Human Immunodeficiency Virus Type 1 Regulator of the Sensitivity of Primary The V 1 / V 2 Domain of gp 120 Is a Global

  2004cites this paper
• Predictive value of primate models for AIDS.

  2004cites this paper
• Immunogen sequence: the fourth tier of AIDS vaccine design

  2004cites this paper
• Preventive HIV-1 Vaccines

  2004cites this paper
• The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.

  2003cites this paper
• Concordant Modulation of Neutralization Resistance and High Infectivity of the Primary Human Immunodeficiency Virus Type 1 MN Strain and Definition of a Potential gp41 Binding Site in gp120

  2003cites this paper
• Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV‐1 group M primary isolates and can be detected in neutralization assays with extended incubation phases

  2003cites this paper
• Mucosal AIDS Vaccines

  2003cites this paper
• Limited Breadth of a T-Helper Cell Response to a Human Immunodeficiency Virus Envelope Protein

  2003cites this paper
• HIV vaccines 1983–2003

  2003cites this paper
• Impact of HIV vaccination on laboratory diagnosis: case reports

  2002influential citation
• Vaccines: New hope for an aids vaccine

  2002cites this paper
• HIV-1 Vaccine Testing, Trial Design, and Ethics

  2002cites this paper
• Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1

  2002cites this paper
• MINIREVIEW Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development

  2001cites this paper
• An Efficient Test for Comparing Sequence Diversity between Two Populations

  2001cites this paper
• An algorithm for mapping positively selected members of quasispecies-type viruses

  2001cites this paper
• Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.

  2001cites this paper
• Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

  2001cites this paper
• AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy.

  2001cites this paper
• The mucosal immunity in HIV-1 exposed seronegative individuals and expression of HIV-1 gp160 protein in transgenic plants

  2001cites this paper
• Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development

  2001cites this paper
• Biological considerations in the development of a human immunodeficiency virus vaccine.

  2000cites this paper
• Vaccines for HIV

  2000cites this paper
• A Comparison of Full-Length Glycoprotein 120 from Incident HIV Type 1 Subtype E and B Infections in Bangkok Injecting Drug Users with Prototype E and B Strains That Are Components of a Candidate Vaccine

  2000cites this paper
• Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees

  2000cites this paper
• Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.

  2000cites this paper
• Genetic Characterization of Incident HIV Type 1 Subtype E and B Strains from a Prospective Cohort of Injecting Drug Users in Bangkok, Thailand

  2000cites this paper
• AIDSVAX® (MN) in Bangkok Injecting Drug Users: A Report on Safety and Immunogenicity, Including Macrophage-Tropic Virus Neutralization

  2000cites this paper
• Some statistical issues in the design of HIV-1 vaccine and treatment trials

  2000cites this paper
• Turning a corner on HIV neutralization?

  2000cites this paper
• Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution

  2000cites this paper
• Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.

  1999cites this paper
• The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.

  1999cites this paper
• Human trials of HIV-1 vaccines.

  1999cites this paper
• Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.

  1999cites this paper
• Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals

  1999cites this paper
• A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.

  1999cites this paper
• Human Antibody Responses to Mature and Immature Forms of Viral Envelope in Respiratory Syncytial Virus Infection: Significance for Subunit Vaccines

  1999cites this paper
• Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination

  1999cites this paper
• Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques

  1999cites this paper
• The role of nonhuman primates in the development of an AIDS vaccine.

  1999cites this paper
• A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation.

  1999cites this paper
• HIV vaccines.

  1999cites this paper
• Genetic Heterogeneity of HIV Type 1 Subtypes in Kimpese, Rural Democratic Republic of Congo

  1999cites this paper
• Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials

  1999cites this paper
• Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

  1998cites this paper
• Why do we not have an HIV vaccine and how can we make one?

  1998cites this paper
• Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

  1998cites this paper
• Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

  1998cites this paper
• Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.

  1998cites this paper
• Role of Preimmunization Virus Sequences in Cellular Immunity in HIV-Infected Patients during HIV Type 1 MN Recombinant gp160 Immunization

  1998cites this paper
• Lessons for AIDS vaccine development from non-AIDS vaccines.

  1998cites this paper
• Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

  1998cites this paper
• Limitations of a molecular clock applied to considerations of the origin of HIV-1.

  1998cites this paper